I presume, if they can renegotiate the safety aspect to be far less onerous with the FDA, it opens up an extremely efficient pathway to develop the entire pipeline of candidates.
That would be a massive gain for a potential suitor. So another strategy to improve an eventual pricing of NEU takeover. And may be done by end of year?
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-154
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 555 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 12.28pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable